[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 23 of about 23
1. Viswambharan JK, Kadambari D, Iyengar KR, Srinivasan K: Feasibility of breast conservation surgery in locally advanced breast cancer downstaged by neoadjuvant chemotherapy: a study in mastectomy specimens using simulation lumpectomy. Indian J Cancer; 2005 Jan-Mar;42(1):30-4
MedlinePlus Health Information. consumer health - Mastectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility of breast conservation surgery in locally advanced breast cancer downstaged by neoadjuvant chemotherapy: a study in mastectomy specimens using simulation lumpectomy.
  • BACKGROUND: The response of locally advanced breast cancer (LABC) to neoadjuvant chemotherapy (NACT) offers these patients previously treated by mastectomy, the chance for breast conservation.
  • Tumors with post-chemotherapy size> 4 cm were margin positive in 10/13 (77%).
  • Tumors with post-chemotherapy size>3 cm were margin positive in 13/24 (54%).
  • Tumors with post-chemotherapy size 3 cm were margin negative in 5/6 (83%).
  • Pre-chemotherapy tumor size and post-chemotherapy tumor size were significantly associated with margin positivity (P=0.003).
  • Tumors in the subareolar location had significantly higher incidence of residual tumor in the nipple areola complex. (P=0.04).
  • Margin positivity of lumpectomy on downstaged tumors can be reduced by removing the nipple areola complex in subareolar tumors and by limiting breast conservation to tumors with post-chemotherapy size < or =3 cm.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / surgery. Mastectomy / methods. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15805689.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] India
  •  go-up   go-down


2. Sauter ER, Ehya H, Mammen A, Klein G: Nipple aspirate cytology and pathologic parameters predict residual cancer and nodal involvement after excisional breast biopsy. Br J Cancer; 2001 Dec 14;85(12):1952-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nipple aspirate cytology and pathologic parameters predict residual cancer and nodal involvement after excisional breast biopsy.
  • We previously demonstrated that abnormal nipple aspirate fluid (NAF) cytology predicted residual breast cancer (RC) and tumour size after excisional biopsy (EB), although normal NAF cytology did not exclude RC.
  • LN metastases provide prognostic information allowing medical and radiation oncologists to determine the need for adjuvant therapy.
  • NAF cytology and pathologic parameters: tumour distance from biopsy margins, multifocal and multicentric disease, sub-type of ductal carcinoma in situ (DCIS) or invasive cancer (IC), grade of DCIS or IC, tumour and specimen size, tumour and biopsy cavity location, presence or absence of extensive DCIS, and biopsy scar distance from the nipple were evaluated bivariately and then by logistic regression (LR) for their association with RC and involved LN (> or = 1 (+) LN, useful to determine chemotherapy need, and > or = 4 (+) LN, useful to determine radiation need to the chest and axilla).
  • We propose an algorithm which, if confirmed in a larger study, may allow clinicians to be more selective in their recommendations of re-excision breast biopsy or mastectomy.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Dec;81(7):1222-7 [10584885.001]
  • [Cites] J Natl Cancer Inst. 1975 Apr;54(4):829-34 [1168727.001]
  • [Cites] Am J Clin Pathol. 1975 Dec;64(6):728-38 [1202937.001]
  • [Cites] J Natl Cancer Inst. 1983 Dec;71(6):1115-21 [6581355.001]
  • [Cites] Br J Cancer. 1997;76(4):494-501 [9275027.001]
  • [Cites] Semin Surg Oncol. 1992 May-Jun;8(3):122-8 [1496221.001]
  • [Cites] Arch Surg. 1993 Sep;128(9):1014-8; discussion 1018-20 [8396387.001]
  • [Cites] Ann Surg. 1993 Dec;218(6):729-34 [8257222.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Dec;5(12):967-70 [8959318.001]
  • [Cites] Am J Epidemiol. 1992 Jan 15;135(2):130-41 [1536131.001]
  • (PMID = 11747339.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 87391
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  • [Other-IDs] NLM/ PMC2364009
  •  go-up   go-down


3. Horii R, Akiyama F, Kasumi F, Koike M, Sakamoto G: Spontaneous " healing" of breast cancer. Breast Cancer; 2005;12(2):140-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous " healing" of breast cancer.
  • BACKGROUND: Healing is a phenomenon by which the intraductal component of breast cancer disappears and is replaced by fibrous tissue.
  • OBJECTIVE: To clarify the clinicopathological characteristics of breast cancer with healing.
  • PATIENTS AND METHODS: At our hospital, 308 patients (311 breasts) underwent breast conservation therapy without neoadjuvant chemotherapy for breast cancer in 2000.
  • We assessed the proportion and the characteristics of breast cancer with healing. RESULTS:.
  • (1) The proportion of breast cancer with healing was 7% (21/311). (2) In the 21 patients, the mean age was 59.2 years, and the mean diameter was 2.8 cm. (3) The histological type of the breast cancer varied: noninvasive ductal carcinoma in 2 cases, papillotubular carcinoma in 5, solid-tubular carcinoma in 8, scirrhous carcinoma in 5, invasive lobular carcinoma in 1, and Paget's disease in 1.
  • However in all cases, the histologic type of the intraductal carcinoma foci was the comedo/solid type and the nuclear grade of cancer cells was high. (4) In cases with healing, areas of healing were seen in an average of 5 (1-26) blocks, compared with intraductal carcinoma foci in 13 blocks (2-40).
  • Healing was located on the nipple side of the main lesion in 8 cases, the peripheral side in 9, and both sides in 4.
  • CONCLUSION: The proportion of breast cancer cases with healing was 7% and these cases were intraductal carcinoma of the comedo/solid type, consisting of highly malignant cancer cells.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / therapy. Carcinoma / therapy. Neoplasm Regression, Spontaneous / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Fibrosis. Humans. Mastectomy, Segmental. Middle Aged

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15858446.001).
  • [ISSN] 1340-6868
  • [Journal-full-title] Breast cancer (Tokyo, Japan)
  • [ISO-abbreviation] Breast Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Huang EH, Tucker SL, Strom EA, McNeese MD, Kuerer HM, Hortobagyi GN, Buzdar AU, Valero V, Perkins GH, Schechter NR, Hunt KK, Sahin AA, Buchholz TA: Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys; 2005 Jun 1;62(2):351-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy.
  • PURPOSE: To identify the clinical and pathologic factors predictive of locoregional recurrence (LRR) after neoadjuvant chemotherapy, mastectomy, and radiotherapy.
  • METHODS AND MATERIALS: We retrospectively reviewed the hospital records of 542 patients treated on six consecutive institutional prospective trials using neoadjuvant chemotherapy and postmastectomy radiotherapy.
  • The clinical factors associated with LRR included combined clinical stage, clinical T stage, ipsilateral supraclavicular nodal disease, chemotherapy response, physical examination size after chemotherapy, and no tamoxifen use (p < or = 0.04 for all factors).
  • The pathologic predictors of LRR included the number of positive nodes, dissection of <10 nodes, multifocal/multicentric disease, lymphovascular space invasion, extracapsular extension, skin/nipple involvement, and estrogen receptor-negative disease (p <or = 0.05 for all factors).
  • Multivariate Cox regression analysis revealed that five factors independently predicted for LRR: skin/nipple involvement, supraclavicular nodal disease, no tamoxifen use, extracapsular extension, and estrogen receptor-negative disease (hazard ratio, 2.1-2.8; p < or = 0.02 for all factors).
  • CONCLUSION: Although the long-term rate of LRR after neoadjuvant chemotherapy, mastectomy, and radiotherapy is low, we identified a number of factors that correlated independently with greater rates of LRR.
  • Patients with three or more of these factors may benefit from research protocols investigating alternative treatment strategies.
  • [MeSH-major] Breast Neoplasms / drug therapy. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Clinical Trials as Topic. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Mastectomy. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Neoplasm Staging. Nipples / pathology. Regression Analysis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890574.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / T32CA77050
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


5. Lerouge D, Touboul E, Lefranc JP, Genestie C, Moureau-Zabotto L, Blondon J: [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients]. Cancer Radiother; 2004 Jun;8(3):155-67
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Locally advanced non inflammatory breast cancer treated by combined chemotherapy and preoperative irradiation: updated results in a series of 120 patients].
  • [Transliterated title] Cancer du sein localement évolué non inflammatoire traité par association de chimiothérapie et de radiothérapie à dose préopératoire: réactualisation des résultats d'une série de 120 patientes.
  • PURPOSE: To evaluate our updated data concerning survival and locoregional control in a study of locally advanced non inflammatory breast cancer after primary chemotherapy followed by external preoperative irradiation.
  • PATIENTS AND METHODS: Between 1982 and 1998, 120 patients (75 stage IIIA, 41 stage IIIB, and 4 stage IIIC according to AJCC staging system 2002) were consecutively treated by four courses of induction chemotherapy with anthracycline-containing combinations followed by preoperative irradiation (45 Gy to the breast and nodal areas) and a fifth course of chemotherapy.
  • After completion of local therapy, all patients received a sixth course of chemotherapy and a maintenance adjuvant chemotherapy regimen without anthracycline.
  • The median follow-up from the beginning of treatment was 140 months.
  • RESULTS: Mastectomy and axillary dissection were performed in 49 patients (with residual tumour larger than 3 cm in diameter or located behind the nipple or with bifocal tumour), and conservative treatment in 71 patients (39 achieved clinical complete response or partial response >90% and received additional radiation boost to initial tumour bed; 32 had residual mass <or=3 cm in diameter and were treated by wide excision and axillary dissection followed by a boost to the excision site).
  • After multivariate analysis, possibility of breast-conserving therapy was related to initial tumour size (<6 vs. >or=6 cm in diameter, p =0.002).
  • After multivariate analysis, metastatic disease-free survival rates were significantly influenced by clinical stage (stage IIIA-B vs. IIIC, p =0.0003), N-stage (N0 vs. N1-2a, and 3c, p =0.017), initial tumour size (<6 vs. >or=6 cm in diameter, p =0.008), and tumour response after induction chemotherapy and preoperative irradiation (clinically complete response + partial response vs. non-response, p =0.0015).
  • In the non conservative breast treatment group, of the 32 patients with no change in clinical tumour size after induction chemotherapy, the 10-year metastatic disease-free survival rate was 59% with only one local relapse.
  • CONCLUSION: Despite the poor prognosis of patients with locally advanced non inflammatory breast cancer resistant to primary anthracycline-based regimen, aggressive locoregional management using preoperative irradiation and mastectomy with axillary dissection offers a possibility of long term survival with low local failure rate for patients without extensive nodal disease.
  • On the other hand, the rate of local failure seems to be high in patients with clinical partial tumour response following induction chemotherapy and breast-conserving treatment combining preoperative irradiation and large wide excision.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Mastectomy. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Inflammatory breast cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15217583.001).
  • [ISSN] 1278-3218
  • [Journal-full-title] Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
  • [ISO-abbreviation] Cancer Radiother
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


6. Seetharam S, Fentiman IS: Paget's disease of the nipple. Womens Health (Lond); 2009 Jul;5(4):397-402
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paget's disease of the nipple.
  • Paget's disease of the nipple is an unusual epidermal presentation of underlying breast cancer.
  • Mastectomy maximizes local control; however, selected cases can be treated by nipple conisation with radiotherapy.
  • Almost all invasive cases overexpress human EGF receptor-2 and, therefore, are likely to benefit from adjuvant chemotherapy and herceptin.
  • [MeSH-major] Breast Neoplasms / diagnosis. Nipples / pathology. Paget's Disease, Mammary / diagnosis
  • [MeSH-minor] Axilla / pathology. Female. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness / diagnosis. Receptor, ErbB-2 / metabolism. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19586431.001).
  • [ISSN] 1745-5065
  • [Journal-full-title] Women's health (London, England)
  • [ISO-abbreviation] Womens Health (Lond)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / ERBB2 protein, human; EC 2.7.10.1 / Receptor, ErbB-2
  • [Number-of-references] 22
  •  go-up   go-down


7. Naguib SF: Oncoplastic resection of retroareolar breast cancer: central quadrantectomy and reconstruction by local skin-glandular flap. J Egypt Natl Canc Inst; 2006 Dec;18(4):334-47
MedlinePlus Health Information. consumer health - Breast Reconstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncoplastic resection of retroareolar breast cancer: central quadrantectomy and reconstruction by local skin-glandular flap.
  • BACKGROUND: Patients with central breast neoplasms account for 5 to 20% of breast cancer cases and, for a long time, they have been denied Breast Conservation Surgery (BCS) and conventionally treated with mastectomy.
  • The high incidence of Nipple-Areola-Complex (NAC) involvement usually associated with these tumors necessitates nipple and areolar resection together with an adequate safety margin around the tumor, which yields an unacceptable cosmetic result.
  • In this study central quadrantectomy and breast reconstruction by an infero-laterally based pedicled flap were evaluated.
  • PATIENTS AND METHODS: This study comprised 23 women with central breast tumors treated at the National Cancer Institute (NCI), Cairo University and at the Aswan Cancer Center, Egyptian Ministry of Health.
  • Twenty-two had a palpable mass, while only 1 had Paget's disease of the nipple without mass.
  • Only 9 women showed clinical suspicion of NAC involvement in the form of nipple retraction.
  • All patients underwent central quadrantectomy with NAC resection removing a cylinder of breast tissue reaching down to the pectoral muscle together with axillary dissection.
  • All patients received adjuvant radiotherapy with or without chemotherapy or hormonal therapy.
  • RESULTS: Fourteen patients showed pathological evidence of nipple infiltration (60.8%).
  • The procedure lasted a mean time of 195+/-12.7 minutes and blood loss was estimated at a mean of 225+/-64.8 mL.
  • The procedure did not delay the start of adjuvant treatment nor did it hamper clinical and mammographic follow-up.
  • Central quadrantectomy with repair by a skin-glandular flap is a relatively simple procedure that yields very satisfactory cosmetic results with minimal complications and it may be considered as one of the noteworthy therapeutic options for patients with central breast tumors.
  • [MeSH-major] Breast Neoplasms / surgery. Carcinoma, Ductal / surgery. Carcinoma, Lobular / surgery. Mammaplasty / methods. Mastectomy, Segmental / methods. Skin Transplantation. Surgical Flaps
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Nipples / surgery. Postoperative Complications. Time Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18301457.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


8. Reefy S, Patani N, Anderson A, Burgoyne G, Osman H, Mokbel K: Oncological outcome and patient satisfaction with skin-sparing mastectomy and immediate breast reconstruction: a prospective observational study. BMC Cancer; 2010;10:171
MedlinePlus Health Information. consumer health - Mastectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncological outcome and patient satisfaction with skin-sparing mastectomy and immediate breast reconstruction: a prospective observational study.
  • BACKGROUND: The management of early breast cancer (BC) with skin-sparing mastectomy (SSM) and immediate breast reconstruction (IBR) is not based on level-1 evidence.
  • In this study, the oncological outcome, post-operative morbidity and patients' satisfaction with SSM and IBR using the latissimus dorsi (LD) myocutaneous flap and/or breast prosthesis is evaluated.
  • Nipple reconstruction was performed in 69 patients, using the trefoil local flap technique (n = 61), nipple sharing (n = 6), skin graft (n = 1) and Monocryl mesh (n = 1).
  • Overall breast cancer specific survival was 99.2%, 8 patients developed distant disease and 1 died of metastatic BC.
  • Morbidities included infection, requiring implant removal in 2 patients and 1 patient developed marginal ischaemia of the skin envelope.
  • Chemotherapy was delayed in 1 patient due to infection.
  • [MeSH-major] Breast Neoplasms / surgery. Carcinoma, Intraductal, Noninfiltrating / surgery. Dermatologic Surgical Procedures. Mammaplasty. Mastectomy. Patient Satisfaction
  • [MeSH-minor] Adult. Aged. Breast Implantation. Chemotherapy, Adjuvant. Female. Humans. London. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Nipples / surgery. Radiotherapy, Adjuvant. Skin / pathology. Skin Transplantation. Surgical Flaps. Surveys and Questionnaires. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Reconstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2007 Mar;33(2):140-6 [17112698.001]
  • [Cites] Breast J. 2006 May-Jun;12(3):194-8 [16684314.001]
  • [Cites] Br J Surg. 2007 Oct;94(10):1220-5 [17579346.001]
  • [Cites] Eur J Surg Oncol. 2007 Dec;33(10):1142-5 [17490847.001]
  • [Cites] Eur J Surg Oncol. 2008 Feb;34(2):143-8 [17709228.001]
  • [Cites] Arch Surg. 2008 Jan;143(1):38-45; discussion 45 [18209151.001]
  • [Cites] Breast Cancer Res Treat. 2008 Oct;111(3):391-403 [17965954.001]
  • [Cites] Am Surg. 2008 Oct;74(10):902-5 [18942610.001]
  • [Cites] Ann Surg Oncol. 2008 Dec;15(12):3396-401 [18923874.001]
  • [Cites] Ann Surg. 2009 Mar;249(3):461-8 [19247035.001]
  • [Cites] Ann Surg Oncol. 2000 Aug;7(7):544-8 [10947024.001]
  • [Cites] Ann Surg Oncol. 2002 Mar;9(2):165-8 [11888874.001]
  • [Cites] Ann Surg. 2002 Jun;235(6):814-9 [12035037.001]
  • [Cites] Ann Surg Oncol. 2002 Jun;9(5):462-6 [12052757.001]
  • [Cites] Plast Reconstr Surg. 2003 Feb;111(2):706-11 [12560691.001]
  • [Cites] Ann Surg Oncol. 2003 Mar;10(2):95-7 [12620899.001]
  • [Cites] Ann Surg Oncol. 2003 Mar;10(2):102-7 [12620902.001]
  • [Cites] Ann Surg Oncol. 2003 Mar;10(2):108-12 [12620903.001]
  • [Cites] Eur J Surg Oncol. 2003 Mar;29(2):191-7 [12633565.001]
  • [Cites] Ann Surg. 2003 Jul;238(1):120-7 [12832974.001]
  • [Cites] Surg Clin North Am. 2003 Aug;83(4):885-99 [12875600.001]
  • [Cites] Surg Clin North Am. 2003 Aug;83(4):995-1013 [12875606.001]
  • [Cites] Ann Plast Surg. 2003 Dec;51(6):547-51 [14646645.001]
  • [Cites] Ann Plast Surg. 2004 Jan;52(1):15-21 [14676693.001]
  • [Cites] Plast Reconstr Surg. 2004 Mar;113(3):877-81 [15108879.001]
  • [Cites] Plast Reconstr Surg. 2004 May;113(6):1617-28 [15114121.001]
  • [Cites] Am J Surg. 2004 Jul;188(1):78-84 [15219490.001]
  • [Cites] Plast Reconstr Surg. 1995 Oct;96(5):1111-5; discussion, 1116-8 [7568487.001]
  • [Cites] Ann Surg. 1997 May;225(5):570-5; discussion 575-8 [9193184.001]
  • [Cites] Eur J Surg Oncol. 1998 Feb;24(1):15-6 [9542508.001]
  • [Cites] Plast Reconstr Surg. 1998 Jul;102(1):49-62 [9655407.001]
  • [Cites] Ann Surg Oncol. 1999 Sep;6(6):609-13 [10493632.001]
  • [Cites] Am J Surg. 2005 Dec;190(6):918-22 [16307946.001]
  • [Cites] Am J Surg. 2007 Oct;194(4):438-43 [17826052.001]
  • (PMID = 20429922.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2873394
  •  go-up   go-down


9. Lerouge D, Touboul E, Lefranc JP, Genestie C, Moureau-Zabotto L, Blondon J: Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients. Int J Radiat Oncol Biol Phys; 2004 Jul 15;59(4):1062-73
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients.
  • PURPOSE: To evaluate our updated data concerning survival and locoregional control in a prospective study of locally advanced noninflammatory breast cancer (LABC) after primary chemotherapy (CT) followed by external preoperative irradiation (RT).
  • METHODS AND MATERIALS: Between 1982 and 1998, 120 patients (75 Stage IIIA, 41 Stage IIIB, and 4 Stage IIIC according to AJCC staging system 2002) were treated by four courses of induction CT with anthracycline-containing combinations followed by preoperative RT (45 Gy to the breast and nodal areas) and a fifth course of CT.
  • After completion of local therapy, all patients received a sixth course of CT and a maintenance adjuvant CT regimen without anthracycline.
  • The median follow-up from the beginning of treatment was 140 months.
  • RESULTS: Mastectomy and axillary dissection were performed in 49 patients (with residual tumor larger than 3 cm in diameter or located behind the nipple or with bifocal tumor), and conservative treatment in 71 patients (39 achieved clinical complete response or partial response >90% and received additional radiation boost to initial tumor bed; 32 had residual mass < or =3 cm in diameter and were treated by wide excision and axillary dissection followed by a boost to the excision site).
  • After multivariate analysis, possibility of breast-conserving therapy was related to initial tumor size (<6 cm vs. > or =6 cm in diameter, p = 0.002).
  • In the nonconservative breast treatment group, of the 32 patients with no change in clinical tumor size after induction CT, the 10-year metastatic disease-free survival rate was 59% with only one local relapse.
  • On the other hand, the rate of local failure seems to be high in patients with clinical partial tumor response after induction CT and breast-conserving treatment combining preoperative RT and large wide excision.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Axilla. Chemotherapy, Adjuvant. Cobalt Radioisotopes / therapeutic use. Female. Follow-Up Studies. Humans. Lymph Node Excision. Mastectomy, Segmental. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prospective Studies. Remission Induction. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15234040.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cobalt Radioisotopes
  •  go-up   go-down


10. Fan ZM, Song D, Wang L, Fu T, Yang M, Liu GJ: [Total mastectomy and axillary dissection with conservation of the nipple-areola complex, and immediate reconstruction with artificial prosthesis in the treatment of early breast cancer]. Zhonghua Yi Xue Za Zhi; 2007 Jan 9;87(2):93-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Total mastectomy and axillary dissection with conservation of the nipple-areola complex, and immediate reconstruction with artificial prosthesis in the treatment of early breast cancer].
  • OBJECTIVE: To study the feasibility of total mastectomy and axillary dissection with conservation of the nipple-areola complex, and immediate reconstruction with artificial prosthesis in the treatment of early breast cancer.
  • METHODS: The 20 patients with breast cancer (TNM stage I, 6 patients; stage II, 14 patients) underwent the total mastectomy axillary dissection with conservation of the nipple-areola complex, and immediate reconstruction with artificial prosthesis.
  • Post-operation they were given chemotherapy, radiotherapy, endocrine therapy.
  • CONCLUSION: Total mastectomy and axillary dissection with conservation of the nipple-areola complex, and immediate reconstruction with artificial prosthesis on selected patients with breast cancer is an oncologically acceptable procedure with superior cosmetic results, without increasing the risk of local recurrences, complications and influencing the effects of postoperative adjuvant treatment.
  • [MeSH-major] Breast Implantation. Breast Neoplasms / surgery. Mastectomy, Modified Radical / methods
  • [MeSH-minor] Adult. Feasibility Studies. Female. Follow-Up Studies. Humans. Neoplasm Staging. Nipples / surgery

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17418014.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


11. Madej B, Balak B, Winkler I, Burdan F: Cancer of the accessory breast--a case report. Adv Med Sci; 2009;54(2):308-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer of the accessory breast--a case report.
  • Breast neoplasm may develop in ectopically located glandular tissue.
  • This paper presents an interesting and rare case of a 50-year-old female who despite regular mammography screening examination developed an invasive accessory breast cancer.
  • The lesion was immobile, the skin and the atrophic nipple were retracted, the tumour infiltrated the thoracic wall.
  • Oligobiopsy and additional examinations showed an invasive stage IIIB ductal breast cancer (Bloom II, G-2).
  • The patient was submitted to pre-operative chemotherapy.
  • She also underwent surgery and subsequently post-operative chemotherapy and radiotherapy.
  • On the basis of the presented case, it could be concluded that the accessory mammary glands are out of the image of screening breast examinations.
  • Accessory breast cancer is usually diagnosed by clinical examination and ultrasonography.
  • Preventive resection of accessory breast in women at high risk of developing breast cancer can be considered as the treatment of choice in most patients.
  • [MeSH-major] Breast / pathology. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / pathology. Choristoma / pathology. Skin Diseases / pathology
  • [MeSH-minor] Biopsy. Female. Humans. Mammary Glands, Human / pathology. Middle Aged. Mucin-1 / analysis. Neoplasm Invasiveness. Neoplasm Staging. Nipples / pathology. Receptor, ErbB-2 / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis


12. Kronowitz SJ, Hunt KK, Kuerer HM, Strom EA, Buchholz TA, Ensor JE, Koutz CA, Robb GL: Practical guidelines for repair of partial mastectomy defects using the breast reduction technique in patients undergoing breast conservation therapy. Plast Reconstr Surg; 2007 Dec;120(7):1755-68
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Practical guidelines for repair of partial mastectomy defects using the breast reduction technique in patients undergoing breast conservation therapy.
  • BACKGROUND: The authors previously compared the local tissue rearrangement, breast reduction, and latissimus dorsi flap reconstruction techniques for repairing partial mastectomy defects and showed the benefits of breast reduction.
  • METHODS: In this study, the authors focused solely on factors influencing outcome in 41 patients who underwent repair of a partial mastectomy defect using breast reduction.
  • Fifty percent of the lower outer and central quadrant tumors required an amputative design with a free nipple graft.
  • Tumors in the upper outer quadrant of the breast were associated with the highest complication rate (35 percent).
  • Ninety percent of patients with planned repairs had a viable nipple-areola complex (p = 0.05) and did not require a free nipple graft.
  • More favorable cosmetic outcomes were achieved using an inferior pedicle; less favorable cosmetic outcomes were achieved for tumors in the upper inner quadrant of the breast.
  • Five percent of patients developed local breast cancer recurrence after a mean follow-up of 36 months.
  • CONCLUSION: The authors provide practical guidelines for repairing a partial mastectomy defect using breast reduction that should minimize the occurrence of complications and optimize the cosmetic outcome.
  • [MeSH-minor] Adult. Breast Neoplasms / drug therapy. Breast Neoplasms / radiotherapy. Breast Neoplasms / surgery. Carcinoma, Ductal, Breast / drug therapy. Carcinoma, Ductal, Breast / radiotherapy. Carcinoma, Ductal, Breast / surgery. Chemotherapy, Adjuvant. Combined Modality Therapy. Esthetics. Fat Necrosis / epidemiology. Fat Necrosis / etiology. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Nipples / surgery. Postoperative Complications / epidemiology. Postoperative Complications / prevention & control. Practice Guidelines as Topic. Retrospective Studies. Seroma / epidemiology. Seroma / etiology. Surgical Flaps. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Breast Reconstruction.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Plast Reconstr Surg. 2008 Aug;122(2):675-6; author reply 676-7 [18626402.001]
  • (PMID = 18090737.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Mannell A: Breast-conserving therapy in breast cancer patients--a 12-year experience. S Afr J Surg; 2005 May;43(2):28-30; discussion 30, 32
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast-conserving therapy in breast cancer patients--a 12-year experience.
  • INTRODUCTION: Twenty years ago prospective randomised controlled trials were initiated to compare conservative breast surgery plus radiation with radical mastectomy in the treatment of early-stage breast cancer.
  • The results have shown no survival advantage for mastectomy over breast-conserving therapy (BCT).
  • METHODS: This retrospective study was performed on 165 breast cancer patients undergoing BCT in the 12 years up to August 2002.
  • Adjuvant therapy (hormones, chemotherapy) was undertaken, and the incidence and times of local recurrence and distant metastases were recorded.
  • At a median follow-up of 65 months one patient developed local recurrence (LR) in the breast synchronously with distant relapse.
  • Two patients had non-nodal axillary recurrences but no patient suffered LR in isolation in the treated breast.
  • The segment containing the cancer should be resected from the nipple to the periphery of the breast.
  • [MeSH-major] Breast Neoplasms / surgery. Carcinoma, Ductal / surgery. Carcinoma, Intraductal, Noninfiltrating / surgery. Mastectomy, Segmental
  • [MeSH-minor] Combined Modality Therapy. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16035379.001).
  • [ISSN] 0038-2361
  • [Journal-full-title] South African journal of surgery. Suid-Afrikaanse tydskrif vir chirurgie
  • [ISO-abbreviation] S Afr J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] South Africa
  •  go-up   go-down


14. Sardanelli F, Boetes C, Borisch B, Decker T, Federico M, Gilbert FJ, Helbich T, Heywang-Köbrunner SH, Kaiser WA, Kerin MJ, Mansel RE, Marotti L, Martincich L, Mauriac L, Meijers-Heijboer H, Orecchia R, Panizza P, Ponti A, Purushotham AD, Regitnig P, Del Turco MR, Thibault F, Wilson R: Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer; 2010 May;46(8):1296-316
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group.
  • The use of breast magnetic resonance imaging (MRI) is rapidly increasing.
  • EUSOMA organised a workshop in Milan on 20-21st October 2008 to evaluate the evidence currently available on clinical value and indications for breast MRI.
  • Twenty-three experts from the disciplines involved in breast disease management - including epidemiologists, geneticists, oncologists, radiologists, radiation oncologists, and surgeons - discussed the evidence for the use of this technology in plenary and focused sessions.
  • For the following ten indications, an overview of the evidence, a list of recommendations, and a number of research issues were defined: staging before treatment planning; screening of high-risk women; evaluation of response to neoadjuvant chemotherapy; patients with breast augmentation or reconstruction; occult primary breast cancer; breast cancer recurrence; nipple discharge; characterisation of equivocal findings at conventional imaging; inflammatory breast cancer; and male breast.
  • The working group strongly suggests that all breast cancer specialists cooperate for an optimal clinical use of this emerging technology and for future research, focusing on patient outcome as primary end-point.
  • [MeSH-major] Breast Neoplasms / diagnosis. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Chemotherapy, Adjuvant. Evidence-Based Medicine. Female. Humans. Italy. Male. Mammaplasty. Neoplasm Recurrence, Local / diagnosis. Patient Selection

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20304629.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article
  • [Publication-country] England
  • [Number-of-references] 223
  •  go-up   go-down


15. Caliskan M, Gatti G, Sosnovskikh I, Rotmensz N, Botteri E, Musmeci S, Rosali dos Santos G, Viale G, Luini A: Paget's disease of the breast: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat; 2008 Dec;112(3):513-21
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paget's disease of the breast: the experience of the European Institute of Oncology and review of the literature.
  • BACKGROUND: Paget's disease of the breast is an uncommon presentation of breast malignancy, accounting for 1-3% of all the breast tumors and presents in different histopathologic patterns: in association with an underlying invasive or non invasive carcinoma, or without any underlying neoplasia.
  • In the literature, different methods are used for the treatment.
  • Mastectomy with or without axillary dissection has been considered as the standard treatment procedure for many years.
  • Several studies have already shown that breast conservation with radiation therapy is an oncologically safe option.
  • The objective of this study was to retrospectively analyze outcome of patients affected by Paget's breast disease and to define our institutional experience.
  • PATIENTS AND METHODS: Between May 1996 and February 2003, 114 patients with confirmed Paget's disease of the breast were retrieved and underwent surgery at the European Institute of Oncology of Milan, Italy.
  • The median age of the patients was 54 years at the time of the diagnosis.
  • Patients underwent either conservative breast surgery or mastectomy, with or without sentinel lymph node biopsy and/or axillary surgery.
  • Each patient was evaluated after surgery at a multidisciplinary meeting to selecting systemic therapy.
  • RESULTS: Seven patients had "pure" Paget's disease of the breast and one hundred seven had the disease associated with an underlying carcinoma.
  • As surgical techniques 71 mastectomies and 43 breast conserving surgeries have been performed.
  • Adjuvant systemic therapies were based on the final tumor, node and metastasis stage: thirty patients received adjuvant chemotherapy alone, fourteen received endocrine treatment alone, twenty-six patients were evaluated to receive both chemo and endocrine therapy.
  • Five patients developed local recurrence, one had regional recurrence, another two had loco-regional recurrences and fourteen had distant metastasis as a first event.
  • Breast conserving surgery combined with breast irradiation for patients with invasive and non invasive breast carcinoma has become the treatment of first choice.
  • All surgical conservative approaches should include the complete nipple-areolar complex and margins of resected specimen free of tumor.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / epidemiology. Paget's Disease, Mammary / diagnosis. Paget's Disease, Mammary / epidemiology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast / pathology. Clinical Trials as Topic. Female. Humans. Mastectomy. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Sentinel Lymph Node Biopsy / methods. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18240020.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


16. Bakheet SM, Bakheet R, Ezzat A, Tulbah A, Durakovic A, Hussain S: F-18 FDG positron emission tomography in primary breast non-Hodgkin's lymphoma. Clin Nucl Med; 2001 Apr;26(4):299-301
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] F-18 FDG positron emission tomography in primary breast non-Hodgkin's lymphoma.
  • A 50-year-old woman had an irregular, mobile, firm right breast mass that became progressively larger in the past 3 months that measured 18 x 15 cm at the time of examination.
  • She had no nipple discharge or skin changes.
  • A 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) showed a ring-shaped breast uptake consisting of high peripheral glycolytic activity and a cold center most likely representing necrosis or hemorrhage despite the absence of a history of trauma, surgical intervention, chemotherapy, or radiation to the breast.
  • These results were confirmed by computed tomography of the chest, abdomen, and pelvis.
  • Cytologic examination of a fine-needle aspiration of the breast mass showed diffuse large B-cell, intermediate grade, non-Hodgkin's lymphoma.
  • Although it occurs infrequently, primary breast lymphoma should be considered in patients with a breast mass that shows a ring-shaped FDG uptake.
  • A PET scan, in contrast to other imagining techniques, offers the advantage of screening the entire body, excluding the presence of metastases, and confirming the primary origin of the breast lymphoma.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Lymphoma, Non-Hodgkin / radionuclide imaging. Radiopharmaceuticals. Tomography, Emission-Computed
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11290887.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


17. Ballester M, Berry M, Couturaud B, Reyal F, Salmon RJ, Fitoussi AD: Lateral mammaplasty reconstruction after surgery for breast cancer. Br J Surg; 2009 Oct;96(10):1141-6
MedlinePlus Health Information. consumer health - Breast Reconstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lateral mammaplasty reconstruction after surgery for breast cancer.
  • BACKGROUND: Up to 60 per cent of cancers develop laterally in the breast and breast-conserving surgery frequently produces superolateral nipple-areolar complex (NAC) distortion aggravated by postoperative irradiation.
  • It is an option when a deformity is anticipated after breast-conserving surgery, and is particularly valuable when neoadjuvant chemotherapy has downgraded a large tumour.
  • [MeSH-major] Breast Neoplasms / surgery. Carcinoma, Ductal, Breast / surgery. Carcinoma, Lobular / surgery. Mammaplasty / methods. Surgical Flaps
  • [MeSH-minor] Adult. Aged. Calcinosis / surgery. Esthetics. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local / surgery. Patient Satisfaction. Postoperative Complications / surgery. Reoperation. Treatment Outcome

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19787762.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Petrocca S, La Torre M, Cosenza G, Bocchetti T, Cavallini M, Di Stefano D, Sammartino F, Ziparo V: Male breast cancer: a case report and review of the literature. Chir Ital; 2005 May-Jun;57(3):365-71
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Male breast cancer: a case report and review of the literature.
  • Breast cancer in men is an uncommon disease.
  • Because of its rarity little is known about its aetiology, clinical behaviour and treatment.
  • Retrospective studies show that when age- and stage-matched breast cancer in men and women are compared, there is no difference in survival between the two groups.
  • Nevertheless, because of the absence of screening protocols and the limited amount of mammary tissue in men, allowing rapid local infiltration, a late diagnosis is often made, with a poor survival rate.
  • Most of our current knowledge about the biology, natural history, surgical therapeutic strategies, adjuvant radiotherapy and chemotherapy protocols of male breast carcinoma has been extrapolated from its female counterpart.
  • The Authors report the case of a male patient with breast cancer and pagetoid diffusion in the nipple region, and, on the basis of a review of the literature, summarise what is currently known about this rare neoplasm in terms of prognostic factors, therapy and survival.
  • [MeSH-major] Breast Neoplasms, Male / pathology. Breast Neoplasms, Male / surgery. Carcinoma, Ductal, Breast / pathology. Carcinoma, Ductal, Breast / surgery
  • [MeSH-minor] Aged. Humans. Male. Mastectomy, Radical / methods. Neoadjuvant Therapy / methods. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Breast Cancer, Male.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16231827.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 39
  •  go-up   go-down


19. Gherardini G, Thomas R, Basoccu G, Zaccheddu R, Fortunato L, Cortino P, Evans GR, Matarasso A, D'Aiuto M, D'Aiuto G: Immediate breast reconstruction with the transverse rectus abdominis musculocutaneous flap after skin-sparing mastectomy. Int Surg; 2001 Oct-Dec;86(4):246-51
MedlinePlus Health Information. consumer health - Mastectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immediate breast reconstruction with the transverse rectus abdominis musculocutaneous flap after skin-sparing mastectomy.
  • Immediate breast reconstruction with the transverse rectus abdominis musculocutaneous (TRAM) flap after skin-sparing mastectomy is becoming an increasingly performed procedure in patients with ductal carcinoma in situ, early invasive breast cancer, and prophylactic mastectomy.
  • Through a periareolar approach, it is possible to remove the breast parenchyma along with the nipple areola complex, preserving almost all the original skin envelope and the inframmamary fold.
  • The TRAM flap is used to recreate the volume and shape of the original breast.
  • The major disadvantages, extensive scar and donor site skin color mismatch, are reduced to a minimum level because the former is limited at the natural border of the nipple areola and the latter can be effectively concealed with proper nipple reconstruction.
  • Thirty-one patients with a mean age of 39 years (range, 26-50 years) who had undergone unilateral or bilateral mastectomy for early breast cancer and immediate breast reconstruction with the pedicled TRAM flap were retrospectively reviewed.
  • Requirements for the skin-sparing mastectomy technique include suitability of donor site tissue for autologous tissue, early breast cancer or ductal carcinoma in situ, and adequate size and shape matching of the contralateral breast.
  • One patient developed abdominal bulging 1 month after the operation, during the administration of chemotherapy.
  • The nicer aesthetic result with oncological safety is achieved with immediate breast reconstruction with the TRAM flap after skin-sparing mastectomy.
  • [MeSH-minor] Adult. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Carcinoma, Intraductal, Noninfiltrating / pathology. Carcinoma, Intraductal, Noninfiltrating / surgery. Female. Humans. Middle Aged. Neoplasm Staging. Rectus Abdominis / surgery. Retrospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Breast Reconstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12056470.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


20. Sauter ER, Ganz PA, Ehya H, Hewett JE, Schlatter L, Kliethermes B, Daly MB: Prospective multicenter trial to determine the feasibility of collection and predictive ability of breast fluid analysis in postmenopausal women receiving SERMs. Breast; 2007 Oct;16(5):489-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective multicenter trial to determine the feasibility of collection and predictive ability of breast fluid analysis in postmenopausal women receiving SERMs.
  • (1) our ability to collect nipple aspirate fluid (NAF) in postmenopausal women taking medication to decrease breast proliferation and (2) NAF biomarkers associated with breast cancer.
  • NAF was collected before and 6 months after starting treatment.
  • We were able to collect fluid in 84% of the subjects who produced NAF at baseline and returned for second aspiration after 6 months of treatment.
  • Median PSA increased from 37.5 to 112 ng/L after treatment.
  • In conclusion, after treatment with tamoxifen or raloxifene, changes in both NAF cytology and PSA were generally favorable, consistent with their expected antiproliferative effective effect on the breast.
  • [MeSH-major] Biopsy, Fine-Needle / methods. Body Fluids / chemistry. Breast Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy. Nipples / pathology. Selective Estrogen Receptor Modulators / therapeutic use
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Postmenopause. Predictive Value of Tests. Prospective Studies. United States

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17482465.001).
  • [ISSN] 0960-9776
  • [Journal-full-title] Breast (Edinburgh, Scotland)
  • [ISO-abbreviation] Breast
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Selective Estrogen Receptor Modulators
  •  go-up   go-down


21. Iizuka M, Sengoku N, Nakakuma T, Yoshimura N, Hayashi K, Enomoto T, Kuranami M, Watanabe M: [A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)]. Gan To Kagaku Ryoho; 2008 Nov;35(12):2228-30
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)].
  • We here describe a case of advanced breast cancer (Stage IV) in which an oral S-1+TAM therapy following a primary systemic chemo-radiotherapy has been effective in maintaining the patient's QOL.
  • A 40-year-old woman visited our hospital because of her left breast tumor.
  • On physical examination, the tumor had invaded to the skin adjacent to the nipple forming a skin ulcer and marked deformity of the entire breast.
  • Accordingly, a primary systemic chemotherapy (4 series of AC/T) was started and followed by local radiation therapy (60 Gys) immediately after completing the chemotherapy.
  • The metastasizing lesions in the liver, lungs, and skull had markedly reduced in the size and number, and the skin ulceration had healed up by these treatments.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Oxonic Acid / therapeutic use. Paclitaxel / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Biopsy. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Doxorubicin / therapeutic use. Drug Combinations. Female. Humans. Mitoxantrone / therapeutic use. Neoplasm Staging. Time Factors. Tomography, X-Ray Computed. Topotecan / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19106579.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Drug Combinations; 04079A1RDZ / Cytarabine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 7M7YKX2N15 / Topotecan; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; P88XT4IS4D / Paclitaxel; AC protocol; TAM protocol
  •  go-up   go-down


22. Matsui K, Tazawa K, Karato M, Nagata T, Shimada Y, Tsukada K: [An elderly advanced breast cancer with a good response to anastrozole]. Gan To Kagaku Ryoho; 2010 Aug;37(8):1557-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An elderly advanced breast cancer with a good response to anastrozole].
  • In December 2005, she became aware of a tumor in her right breast at the nipple, gradually increasing in size and bleeding, and visited our department in April 2006.
  • Roughly 3.5 cm in size, the tumor had a prominent large skin surface, bled profusely, and a dark red-colored was found at the E area of the right breast.
  • Core needle biopsy examination indicated invasive breast cancer (pap-tub), ER(+), PgR(+), HER2(3+).
  • We started anastrozole 1mg/day treatment.
  • We report the long-term effect of aromatase inhibitor for elderly breast cancer patients without operation.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Aromatase Inhibitors / therapeutic use. Breast Neoplasms / drug therapy. Nitriles / therapeutic use. Triazoles / therapeutic use
  • [MeSH-minor] Aged, 80 and over. Female. Humans. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. ANASTROZOLE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20716886.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Triazoles; 2Z07MYW1AZ / anastrozole
  •  go-up   go-down


23. Katz A, Strom EA, Buchholz TA, Theriault R, Singletary SE, McNeese MD: The influence of pathologic tumor characteristics on locoregional recurrence rates following mastectomy. Int J Radiat Oncol Biol Phys; 2001 Jul 1;50(3):735-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: We reviewed the medical records of 1031 patients treated with mastectomy and doxorubicin-based chemotherapy without radiation on 5 prospective clinical trials.
  • Patients with lymph-vascular space invasion (LVSI) or involvement of the skin or nipple also experienced high rates of LRR (25%, 32%, and 50%, respectively).
  • In a separate analysis including only patients with 1-3 involved axillary nodes, microscopic invasion of the skin or nipple, pectoral fascial invasion, and the presence of close or positive margins were significant predictors of LRR.
  • CONCLUSION: In addition to the extent of primary and nodal disease, other factors that predict for high rates of LRR include the presence of LVSI, involvement of the skin, nipple or pectoral fascia, close or positive margins, or gross multicentric disease.
  • [MeSH-major] Breast Neoplasms / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Clinical Trials as Topic. Disease-Free Survival. Female. Humans. Lymphatic Metastasis. Mastectomy. Middle Aged. Neoplasm Invasiveness. Predictive Value of Tests. Risk Factors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11395242.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down






Advertisement